Evolent Health Inc

Evolent Health Inc(EVH)股票分析

$4.800

-0.088 (-1.84%)收盘时

Loading chart…
最高
4.950
开盘
4.860
成交量加权均价
4.83
成交量
1.23M
市值
2.30B
最低
4.755
成交额
5.94M
企业价值/息税折旧摊销前利润(TTM)
20.54

Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.

AI 分析 of Evolent Health Inc (EVH)

买入

Evolent Health Inc is a good buy right now due to its recent price performance and favorable technical indicators. The current price is $4.8, with a recent 5-day change of +5.03% and a 20-day change of +32.96%. The RSI is at 63.566, indicating bullish momentum. However, the main risk is the high net debt-to-EBITDA ratio of 7x, which could lead to capital raising under unfavorable conditions.

分析师评级(13)

上行空间 +94.38%
买入
13 买入
0 持有
0 卖出
当前: 4.80
最低
5.00
平均
9.33
最高
16.00

Citi

2026-08-10

目标价

$6

买入

Canaccord

2026-08-10

目标价

$6

买入

TD Cowen

2026-07-28

目标价

$5

买入

Citi

2026-07-23

目标价

—

中性

Canaccord

2026-07-21

目标价

$7

买入

估值指标

Evolent Health Inc(EVH)当前预期市盈率为 8.62,5 年平均预期市盈率为 68.39。

预期市盈率

合理
5 年均值 P/E
68.39
当前P/E
8.62
高估
239.79
低估
-103.01

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-3976.34
当前EV/EBITDA
20.54
高估
24964.91
低估
-32917.58

预期市销率

低估
5 年均值 P/S
1.11
当前P/S
0.17
高估
1.83
低估
0.39

Alphio AI 对 EVH 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%EVH

$10.23

情景价格

基

基准

基准 · 50%EVH

$8.49

情景价格

悲

悲观

悲观 · 25%EVH

$7.28

情景价格

持有 EVH 的大户

R

Rock Springs Capital Management LP

+ 持有EVH

-11.57%

3个月收益率

事件时间线

2026-08-06 (ET)

08:00:00

Evolent Reports Q2 Revenue of $652.52M, Beating Consensus

08:00:00

2026 Revenue Consensus at $2.5B, Adjusted EBITDA Guidance Tightened to $120M-$135M

2026-05-07 (ET)

07:30:00

Evolent Q1 Revenue at $496.25M, Below Consensus

2026-03-19 (ET)

09:00:00

Evolent Health Appoints Archie Mayani as Chief Product Officer

2026-03-02 (ET)

07:40:00

Oppenheimer Lowers Evolent Health Price Target to $6

资讯

EVH 常见问题 —— 由 Alphio AI 解答

Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner. It operates in the Healthcare sector (SERVICES-MANAGEMENT SERVICES industry).

Evolent Health Inc is a good buy right now due to its recent price performance and favorable technical indicators. The current price is $4.8, with a recent 5-day change of +5.03% and a 20-day change of +32.96%. The RSI is at 63.566, indicating bullish momentum. However, the main risk is the high net debt-to-EBITDA ratio of 7x, which could lead to capital raising under unfavorable conditions.

13 analysts cover EVH: 13 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.33.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易